775 related articles for article (PubMed ID: 12610039)
21. Glucagon-like peptide-1 augments insulin-mediated glucose uptake in the obese state.
Egan JM; Meneilly GS; Habener JF; Elahi D
J Clin Endocrinol Metab; 2002 Aug; 87(8):3768-73. PubMed ID: 12161508
[TBL] [Abstract][Full Text] [Related]
22. A novel hyperglycaemic clamp for characterization of islet function in humans: assessment of three different secretagogues, maximal insulin response and reproducibility.
Fritsche A; Stefan N; Hardt E; Schützenauer S; Häring H; Stumvoll M
Eur J Clin Invest; 2000 May; 30(5):411-8. PubMed ID: 10809901
[TBL] [Abstract][Full Text] [Related]
23. Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects.
Vilsbøll T; Krarup T; Madsbad S; Holst JJ
Regul Pept; 2003 Jul; 114(2-3):115-21. PubMed ID: 12832099
[TBL] [Abstract][Full Text] [Related]
24. GLP-1-induced alterations in the glucose-stimulated insulin secretory dose-response curve.
Brandt A; Katschinski M; Arnold R; Polonsky KS; Göke B; Byrne MM
Am J Physiol Endocrinol Metab; 2001 Aug; 281(2):E242-7. PubMed ID: 11440899
[TBL] [Abstract][Full Text] [Related]
25. Insulinotropic hormone glucagon-like peptide-1-(7-37) appears not to augment insulin-mediated glucose uptake in young men during euglycemia.
Ryan AS; Egan JM; Habener JF; Elahi D
J Clin Endocrinol Metab; 1998 Jul; 83(7):2399-404. PubMed ID: 9661618
[TBL] [Abstract][Full Text] [Related]
26. Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus.
Vilsbøll T; Krarup T; Sonne J; Madsbad S; Vølund A; Juul AG; Holst JJ
J Clin Endocrinol Metab; 2003 Jun; 88(6):2706-13. PubMed ID: 12788877
[TBL] [Abstract][Full Text] [Related]
27. Gut incretin hormones in identical twins discordant for non-insulin-dependent diabetes mellitus (NIDDM)--evidence for decreased glucagon-like peptide 1 secretion during oral glucose ingestion in NIDDM twins.
Vaag AA; Holst JJ; Vølund A; Beck-Nielsen HB
Eur J Endocrinol; 1996 Oct; 135(4):425-32. PubMed ID: 8921824
[TBL] [Abstract][Full Text] [Related]
28. Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients.
Willms B; Werner J; Holst JJ; Orskov C; Creutzfeldt W; Nauck MA
J Clin Endocrinol Metab; 1996 Jan; 81(1):327-32. PubMed ID: 8550773
[TBL] [Abstract][Full Text] [Related]
29. Antidiabetogenic action of glucagon-like peptide-1 related to administration relative to meal intake in subjects with type 2 diabetes.
Gutniak MK; Svartberg J; Hellström PM; Holst JJ; Adner N; Ahrén B
J Intern Med; 2001 Jul; 250(1):81-7. PubMed ID: 11454146
[TBL] [Abstract][Full Text] [Related]
30. Glucagon-like peptide-1 (7-37) augments insulin-mediated glucose uptake in elderly patients with diabetes.
Meneilly GS; McIntosh CH; Pederson RA; Habener JF; Gingerich R; Egan JM; Elahi D
J Gerontol A Biol Sci Med Sci; 2001 Nov; 56(11):M681-5. PubMed ID: 11682575
[TBL] [Abstract][Full Text] [Related]
31. No reactive hypoglycaemia in Type 2 diabetic patients after subcutaneous administration of GLP-1 and intravenous glucose.
Vilsbøll T; Krarup T; Madsbad S; Holst JJ
Diabet Med; 2001 Feb; 18(2):144-9. PubMed ID: 11251679
[TBL] [Abstract][Full Text] [Related]
32. Erythromycin antagonizes the deceleration of gastric emptying by glucagon-like peptide 1 and unmasks its insulinotropic effect in healthy subjects.
Meier JJ; Kemmeries G; Holst JJ; Nauck MA
Diabetes; 2005 Jul; 54(7):2212-8. PubMed ID: 15983224
[TBL] [Abstract][Full Text] [Related]
33. Normalization of fasting glycaemia by intravenous GLP-1 ([7-36 amide] or [7-37]) in type 2 diabetic patients.
Nauck MA; Weber I; Bach I; Richter S; Orskov C; Holst JJ; Schmiegel W
Diabet Med; 1998 Nov; 15(11):937-45. PubMed ID: 9827848
[TBL] [Abstract][Full Text] [Related]
34. Evidence against a rate-limiting role of proinsulin processing for maximal insulin secretion in subjects with impaired glucose tolerance and beta-cell dysfunction.
Stumvoll M; Fritsche A; Stefan N; Hardt E; Häring H
J Clin Endocrinol Metab; 2001 Mar; 86(3):1235-9. PubMed ID: 11238514
[TBL] [Abstract][Full Text] [Related]
35. Normal secretion and action of the gut incretin hormones glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in young men with low birth weight.
Schou JH; Pilgaard K; Vilsbøll T; Jensen CB; Deacon CF; Holst JJ; Vølund A; Madsbad S; Vaag AA
J Clin Endocrinol Metab; 2005 Aug; 90(8):4912-9. PubMed ID: 15899957
[TBL] [Abstract][Full Text] [Related]
36. Blood glucose control in healthy subject and patients receiving intravenous glucose infusion or total parenteral nutrition using glucagon-like peptide 1.
Nauck MA; Walberg J; Vethacke A; El-Ouaghlidi A; Senkal M; Holst JJ; Gallwitz B; Schmidt WE; Schmiegel W
Regul Pept; 2004 Apr; 118(1-2):89-97. PubMed ID: 14759561
[TBL] [Abstract][Full Text] [Related]
37. The insulinotropic actions of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (7-37) in normal and diabetic subjects.
Elahi D; McAloon-Dyke M; Fukagawa NK; Meneilly GS; Sclater AL; Minaker KL; Habener JF; Andersen DK
Regul Pept; 1994 Apr; 51(1):63-74. PubMed ID: 8036284
[TBL] [Abstract][Full Text] [Related]
38. The short half-life of glucagon-like peptide-1 in plasma does not reflect its long-lasting beneficial effects.
Hui H; Farilla L; Merkel P; Perfetti R
Eur J Endocrinol; 2002 Jun; 146(6):863-9. PubMed ID: 12039708
[TBL] [Abstract][Full Text] [Related]
39. Absence of a memory effect for the insulinotropic action of glucagon-like peptide 1 (GLP-1) in healthy volunteers.
Meier S; Hücking K; Ritzel R; Holst JJ; Schmiegel WH; Nauck MA
Horm Metab Res; 2003 Sep; 35(9):551-6. PubMed ID: 14517773
[TBL] [Abstract][Full Text] [Related]
40. Characterisation of beta-cell dysfunction of impaired glucose tolerance: evidence for impairment of incretin-induced insulin secretion.
Fritsche A; Stefan N; Hardt E; Häring H; Stumvoll M
Diabetologia; 2000 Jul; 43(7):852-8. PubMed ID: 10952457
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
